Objective
To determine the prevalence of bladder symptoms in patients with Graves’ disease and assess their abnormalities on urodynamic studies.
Patients and methods
The study comprised 30 consecutive patients (13 female, 17 male, mean age 31 years, sd 10) with active Graves’ disease. Before and after attaining euthyroidism with carbimazole, their bladder symptoms were assessed using a questionnaire adapted from the American Urologic Association voiding symptom score, the serum levels of total triiodo‐l‐thyronine (T3), serum thyroxine (T4) and thyroid‐stimulating hormone (TSH) were measured by radioimmunoassay, and uroflowmetry, cystometry and perineal muscle electromyography were performed.
Results
Twelve of the 30 patients (40%) had the onset of bladder symptoms 1–6 months after the onset of symptoms of Graves’ disease; four of the 12 patients had enuresis. Urodynamic studies were possible in five patients and showed reduced flow rates in all, a significant post‐void residual volume in four, and enlarged bladder capacity and increased perineal muscle electromyographic activity during the voiding phase in three. Voiding disturbances and urodynamic abnormalities resolved after attaining euthyroidism.
Conclusion
Significant bladder symptoms can occur in about 40% of patients with active Graves’ disease but resolve on euthyroidism; in some patients, urodynamic studies show significant abnormalities which are also reversible.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.